

Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests

Name of Advisory Committee Temporary Member: Fernando Martinez, M.D.

Committee: Joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and the Pediatric Advisory Committee

Meeting Date: December 10-11, 2008

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: to discuss the benefit risk assessment of long acting beta-2 adrenergic agonists for the treatment of asthma in adults and children, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
Member of an Advisory Board	Competitor	\$5,001 – 10,000
<b>II. Other Imputed Interests</b>		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_11/17/08\_\_\_\_\_  
Date